Skip to main content
. 2014 Oct 31;7:1987–1996. doi: 10.2147/OTT.S67355

Figure 4.

Figure 4

Three hundred and sixty-three nonsmall cell lung cancer patients were pooled from four studies to assess whether the aberrant CDH13 hypermethylation in nonsmall cell lung cancer was associated with advanced stage.

Notes: Aberrant CDH13 hypermethylation was not significantly higher in advanced nonsmall cell lung cancer (III and IV) than that in early-staged nonsmall cell lung cancer (I and II). Odds ratio, 0.93; 95% CI, 0.57–1.53; P=0.79.

Abbreviations: CI, confidence interval; M–H, Mantel–Haenszel.